ELGX - Endologix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.7097
+0.0395 (+5.89%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.6702
Open0.7200
Bid0.7000 x 100
Ask1.3800 x 100
Day's Range0.6750 - 0.7400
52 Week Range0.6700 - 6.7200
Volume930,732
Avg. Volume987,103
Market Cap73.421M
Beta (3Y Monthly)0.78
PE Ratio (TTM)N/A
EPS (TTM)-0.8100
Earnings DateFeb 19, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.77
Trade prices are not sourced from all markets
  • Business Wire24 days ago

    Endologix Honors Innovators of Aortic Therapy at VEITHsymposium

    Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, today honored four innovators of aortic therapy at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium®), a meeting of endovascular specialists highlighting developments in the treatment of vascular disease. At an event called “Learning from the Past to Shape the Future: Evolution of Aortic Therapy,” Endologix recognized the surgeons who advanced aortic repair therapy and initiated early randomized controlled trials of endovascular aneurysm repair (EVAR). Prior to the early 1990s, patients who were not eligible for open surgical repair were left untreated until early innovators challenged the status quo and developed endovascular grafts.

  • GlobeNewswire27 days ago

    Report: Developing Opportunities within Mednax, Peabody Energy, NIC, Endologix, MobileIron, and QuinStreet — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wirelast month

    Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Endologix, Inc.  , a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to three newly hired employees .

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ELGX earnings conference call or presentation 1-Nov-18 8:30pm GMT

    Q3 2018 Endologix Inc Earnings Call

  • Endologix (ELGX) Reports Q3 Loss, Tops Revenue Estimates
    Zackslast month

    Endologix (ELGX) Reports Q3 Loss, Tops Revenue Estimates

    Endologix (ELGX) delivered earnings and revenue surprises of 40.00% and 9.30%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Endologix: 3Q Earnings Snapshot

    The Irvine, California-based company said it had a loss of 12 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The results topped Wall Street expectations. The average ...

  • Business Wirelast month

    Endologix Reports Third Quarter 2018 Financial Results

    Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2018.

  • Business Wirelast month

    Endologix, Inc. to Present at Two Investor Conferences in November

    Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced that it will present at the following two investor conference

  • Business Wirelast month

    Endologix Announces Pricing of Public Offering of Common Stock

    Endologix, Inc. (ELGX) (“Endologix” or the “Company”), developer and marketer of innovative treatments for aortic disorders, announced today the pricing of a registered underwritten public offering of its common stock for net proceeds of $20.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Endologix. All of the shares sold in the offering were sold by Endologix. In addition, Endologix has granted the underwriter a 30-day option to purchase up to an additional $3.0 million of shares of its common stock.

  • Benzingalast month

    The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

    Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week ...

  • Business Wire2 months ago

    Endologix Announces Public Offering of Common Stock

    Endologix, Inc. (ELGX) (“Endologix” or the “Company”), developer and marketer of innovative treatments for aortic disorders, announced today that it has commenced a registered underwritten public offering of $20.0 million of its shares of common stock. In addition, Endologix has granted the underwriter a 30-day option to purchase up to an additional $3.0 million of its shares of common stock. All of the shares in the offering are to be sold by Endologix.

  • Business Wire2 months ago

    Endologix, Inc. to Announce Third Quarter 2018 Financial Results on November 1, 2018

    Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2018 after the market close on Thursday, November 1, 2018. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. This conference call will also be webcast and can be accessed from the “Investors” section of the Company’s website at www.endologix.com.

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for Barnes & Noble, Boot Barn, Endologix, Pilgrim's Pride, OraSure Technologies, and Genesco — Fundamental Analysis, Key Performance Indications

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire2 months ago

    FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall

    Endologix® Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received notice that the U.S. Food and Drug Administration (FDA) has classified a voluntary recall action that Endologix took in July of this year as a Class I recall. The July recall involved Endologix’s issuance of a Safety Notice to healthcare professionals (HCPs) using the AFX® Endovascular AAA System. The Safety Notice, dated 20 July 2018, provided updated information on comparative AFX Type III endoleak rates, patient-tailored surveillance recommendations, and recommendations for intervening through an AFX device or re-intervening on an AFX device.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Boston Scientific Corporation (NYSE: BSX ) Eli Lilly ...

  • Business Wire2 months ago

    Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range

    Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the third quarter ended September 30, 2018 is expected to be in the range of $34.3 million to $34.7 million. Also, based on current business trends, the Company raised the low end of its fiscal 2018 revenue guidance to $150 million. The Company will host a meeting for financial analysts and investment professionals today at The London Hotel NYC, 151 W. 54th St., New York, NY 10019.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ELGX earnings conference call or presentation 9-Aug-18 8:30pm GMT

    Q2 2018 Endologix Inc Earnings Call

  • Business Wire4 months ago

    Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Endologix, Inc. (ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced the grant of inducement equity awards to three newly appointed executives (together, the “Awardees”). The awards were approved by the Company’s Compensation Committee, which is comprised of independent Directors, on August 7, 2018, as an inducement material to the Awardees’ entry into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4). The inducement grants to the Awardees consisted of (i) options (the “Options”) to purchase up to an aggregate of 538,243 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at an exercise price of (A) $2.74 per share with respect to 381,601 shares of Common Stock underlying the Options, and (B) $2.54 per share with respect to 156,642 shares of Common Stock underlying the Options, and (ii) 185,357 restricted stock units (the “RSUs”).

  • Business Wire4 months ago

    Endologix to Host Investor Meeting on October 2, 2018

    Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced that it will host a meeting for financial analysts and investment professionals at 4:15 p.m.

  • Business Wire4 months ago

    Endologix Appoints Jeffrey S. Brown as Chief Operations Officer

    Endologix, Inc. (ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jeffrey S. Brown as the Company’s Chief Operations Officer, effective as of August 13, 2018. John Onopchenko, Chief Executive Officer of Endologix, Inc., said, “I am very excited to have someone with Jeff’s credentials and industry knowledge joining our executive team.

  • Here's Why Endologix Plummeted 37% Today
    Motley Fool4 months ago

    Here's Why Endologix Plummeted 37% Today

    Earnings guidance isn't what it used to be.

  • Endologix (ELGX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks4 months ago

    Endologix (ELGX) Reports Q2 Loss, Tops Revenue Estimates

    Endologix (ELGX) delivered earnings and revenue surprises of 5.26% and 0.88%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press4 months ago

    Endologix: 2Q Earnings Snapshot

    The Irvine, California-based company said it had a loss of 28 cents per share. Losses, adjusted for non-recurring costs, came to 18 cents per share. The results beat Wall Street expectations. The average ...

  • Business Wire4 months ago

    Endologix Reports Second Quarter 2018 Financial Results

    Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2018.